Our group reported that DCV showed an increased immune response in the tumor (higher pCR), its milieu (a rise in TIL and PD-L1 expression) and the peripheral blood (phenotypic changes in immune cells, increased lymphocyte proliferation, IFN-γ production and humoral responses) in paired samples. The gene discussed is CD274; the disease is neoplasm.